AB-M102 / Assembly Biosci - LARVOL DELTA

Nipah Virus Therapeutics: A Systematic Review for Clinical Prioritisation (ASTMH 2023) - "Limited data were available in humans with only one clinical trial (a phase 1 study of the anti-Hendra G glycoprotein m Ab m102.4 in healthy volunteers), and 8 outbreak reports, 7 of which were case series of <10 patients and 6 of which used ribavirin...Only m102.4, remdesivir, ribavirin, and fusion inhibitory lipopeptide have been tested in non-human primates...Risk of bias was critical in all clinical studies other than the one trial and high or unclear in all except one of the animal studies. A rationale is presented for clinical prioritisation."

Clinical • Review • Infectious Disease